OncoTAb

Onco T Ab

Biotechnology, 9201 University City BLVD, Charlotte, North Carolina, 28223, United States, 1-10 Employees

oncotab.com

  • facebook
  • twitter
  • LinkedIn

Who is ONCOTAB

OncoTAb, Inc., a North Carolina based biotechnology company, was founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unme...

Read More

map
  • 9201 University City BLVD, Charlotte, North Carolina, 28223, United States Headquarters: 9201 University City BLVD, Charlotte, North Carolina, 28223, United States
  • 2011 Date Founded: 2011
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8221 | NAICS Code: 62 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ONCOTAB

OncoTAb Org Chart and Mapping

Employees

Pinku Mukherjee

Founder, President & Chief Science Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding OncoTAb

Answer: OncoTAb's headquarters are located at 9201 University City BLVD, Charlotte, North Carolina, 28223, United States

Answer: OncoTAb's official website is https://oncotab.com

Answer: OncoTAb's revenue is $1 Million to $5 Million

Answer: OncoTAb's SIC: 8221

Answer: OncoTAb's NAICS: 62

Answer: OncoTAb has 1-10 employees

Answer: OncoTAb is in Biotechnology

Answer: OncoTAb contact info: Phone number: Website: https://oncotab.com

Answer: OncoTAb, Inc., a North Carolina based biotechnology company, was founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The company has just launched its first product: AgkuraTM Personal Score a simple, non-invasive blood test that aids breast cancer detection in women with dense breast tissue. Roughly half of the women in the US have dense breast tissue and mammograms miss 50% of the breast cancers in these women, resulting in late stage diagnosis and mortality. AgkuraTM Personal Score measures the biomarker tumor-associated MUC1 (tMUC1) and shows a trend of increasing value from benign disease through breast cancer stages 1 to 4. Women can monitor their personal score in conjunction with annual mammograms. A score above the normal range or an increase greater than normal variation will trigger a recommendation for diagnostic imaging (ultrasound or MRI), resulting in earlier stage diagnosis of breast cancer. The company is also working on developing treatments for breast and pancreatic cancers.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access